{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:27:17Z","timestamp":1780493237736,"version":"3.54.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1911,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T00:00:00Z","timestamp":1600992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860068"],"award-info":[{"award-number":["81860068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860068"],"award-info":[{"award-number":["81860068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sacubitril-valsartan has been shown to have superior effects over angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure (HF) and hypertension. The efficacy and safety of sacubitril-valsartan in patients with HF are controversial. We performed a meta-analysis of randomized controlled trials to assess and compare the effect and adverse events of sacubitril-valsartan, valsartan, and enalapril in patients with HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a systematic search using PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov. Randomized controlled trials involving the use of sacubitril-valsartan in patients with HF were included. We assessed the pooled odds ratio (OR) of all-cause mortality, cardiovascular mortality, and hospitalization for HF in fixed-effects models and the pooled risk ratio (RR) of symptomatic hypotension, worsening renal function, and hyperkalaemia in fixed-effects models. Of the 315 identified records, six studies involving 14 959 patients were eligible for inclusion. Sacubitril-valsartan reduced the endpoints of all-cause mortality and cardiovascular mortality in patients with HF with reduced ejection fraction (HFrEF) in three trials with pooled ORs of 0.83 (P = 0.0006) and 0.78 (P &amp;lt; 0.0001), respectively. Regarding the composite outcome of hospitalization for HF in five trials, the pooled OR was 0.79 (P &amp;lt; 0.00001). Compared with enalapril or valsartan, sacubitril-valsartan was associated with a high risk of symptomatic hypotension (RR 1.47, P &amp;lt; 0.00001), low risk of worsening renal function (RR 0.81, P = 0.005), and low rate of serious hyperkalaemia (\u22656.0 mmol\/L) (RR 0.76, P = 0.0007) in all six trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, sacubitril-valsartan significantly decreased the risk of death from all causes or cardiovascular causes in HFrEF and hospitalization for HF in both patients with HFrEF and HF with preserved ejection fraction. Sacubitril-valsartan reduced the risk of renal dysfunction and serious hyperkalaemia but was associated with more symptomatic hypotension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12974","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:53:37Z","timestamp":1601056417000},"page":"3841-3850","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and Safety of Sacubitril-Valsartan in Heart Failure: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1093","volume":"7","author":[{"given":"Hongzhou","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieqiu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University , No. 1, Minde Road, Donghu District, Nanchang, Jiangxi, 330006 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"2026012114073752700_ehf212974-bib-0001","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114073752700_ehf212974-bib-0002","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1388-9842(01)00123-4","article-title":"Economics of chronic heart failure","volume":"3","author":"Berry","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0003","article-title":"Heart disease and stroke statistics\u20142014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"2026012114073752700_ehf212974-bib-0004","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMsa0803563","article-title":"Rehospitalizations among patients in the Medicare fee-for-service program","volume":"360","author":"Jencks","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012114073752700_ehf212974-bib-0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10741-019-09790-5","article-title":"Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials","volume":"24","author":"Yang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2026012114073752700_ehf212974-bib-0006","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jacc.2015.02.009","article-title":"Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations","volume":"65","author":"Asgar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012114073752700_ehf212974-bib-0007","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"2026012114073752700_ehf212974-bib-0008","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"2026012114073752700_ehf212974-bib-0009","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2026012114073752700_ehf212974-bib-0010","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0011","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114073752700_ehf212974-bib-0012","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"},{"key":"2026012114073752700_ehf212974-bib-0013","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114073752700_ehf212974-bib-0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114073752700_ehf212974-bib-0015","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2026012114073752700_ehf212974-bib-0016","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","journal-title":"JAMA"},{"key":"2026012114073752700_ehf212974-bib-0017","volume-title":"Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, Institute of Medicine. Clinical Practice Guidelines We Can Trust","year":"2011"},{"key":"2026012114073752700_ehf212974-bib-0018","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","article-title":"Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF","volume":"75","author":"Vaduganathan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114073752700_ehf212974-bib-0019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/FJC.0000000000000782","article-title":"Sacubitril-valsartan for the treatment of heart failure: time for a paragon?","volume":"75","author":"Del Buono","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114073752700_ehf212974-bib-0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2020.04.011","article-title":"Heart failure with preserved ejection fraction diagnosis and treatment: an updated review of the evidence","author":"Del Buono","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2026012114073752700_ehf212974-bib-0021","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"key":"2026012114073752700_ehf212974-bib-0022","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0023","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol"},{"key":"2026012114073752700_ehf212974-bib-0024","doi-asserted-by":"crossref","first-page":"214","DOI":"10.23736\/S0026-4725.19.04869-2","article-title":"Antihypertensive effect of sacubitril\/valsartan: a meta-analysis","volume":"67","author":"De Vecchis","year":"2019","journal-title":"Minerva Cardioangiol"},{"key":"2026012114073752700_ehf212974-bib-0025","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114073752700_ehf212974-bib-0026","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","article-title":"Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril: The PARADIGM-HF trial (prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure)","volume":"11","author":"Vardeny","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0027","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ejhf.1054","article-title":"Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study","volume":"20","author":"Senni","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0028","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2026012114073752700_ehf212974-bib-0029","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2026012114073752700_ehf212974-bib-0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/FJC.0b013e318210fc7e","article-title":"Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat","volume":"57","author":"Hegde","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012114073752700_ehf212974-bib-0031","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin\u2013angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0032","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0033","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.cardfail.2015.07.008","article-title":"Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact","volume":"21","author":"Buggey","year":"2015","journal-title":"J Card Fail"},{"key":"2026012114073752700_ehf212974-bib-0034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bcpt.12453","article-title":"LCZ696 (valsartan\/sacubitril)\u2014a possible new treatment for hypertension and heart failure","volume":"118","author":"Andersen","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026012114073752700_ehf212974-bib-0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012114073752700_ehf212974-bib-0036","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012114073752700_ehf212974-bib-0037","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2026012114073752700_ehf212974-bib-0038","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12974","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12974","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3841\/65901526\/eschf_7_6_3841.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3841\/65901526\/eschf_7_6_3841.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:08:15Z","timestamp":1769022495000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/6\/3841\/8372395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,9,25]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12974","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,25]]},"assertion":[{"value":"2020-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}